25 May 2023
BerGenBio ASA: BerGenBio Announces Abstracts Accepted for Presentation at 2023 ASCO
– Oral presentation to reveal data from trial evaluating bemcentinib in relapsed mesothelioma –
– Trial-in-Progress poster to be presented regarding the BGBC016 1L STK11m NSCLC trial –
BERGEN, Norway, May 25, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that the Company will be presenting two abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago June 2-6, 2023.
An oral presentation will highlight the results of MIST3, an investigator led, multi-center Phase IIa study led by Professor Dean Fennell at the University of Leicester, UK that assessed the use of bemcentinib in combination with pembrolizumab in patients with relapsed mesothelioma.
A Trial-in-Progress poster will outline the plans for the ongoing BGBC016 Phase 1b/2a study evaluating bemcentinib in combination with pembrolizumab and chemotherapy in 1L STK11m NSCLC patients.
The abstracts will be available in Scientific Presentations (https://www.bergenbio.com/investors/presentations/) on the Company’s website shortly after their presentations at the conference.
ASCO Abstract Details:
Oral Presentation
Title: Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy (https://meetings.asco.org/abstracts-presentations/222514)
Abstract Number: 8511
Abstract Session: Lung Cancer
Presenter: Matthew Krebs, Ph.D., FRCP, Christie Hospital, Manchester, UK
Date/Time: Monday 5th June, 11.30am – 1.00pm
Poster Presentation
Title: Phase 1b/2a safety and tolerability study of bemcentinib (BEM) with pembrolizumab/carboplatin/pemetrexed in first line (1L) advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation (https://meetings.asco.org/abstracts-presentations/226055)
Abstract Number: TPS9154
Poster Number: 134b
Abstract Session: Lung Cancer – Non-Small Cell Metastatic
Presenter: Rajwanth Veluswamy, MD, MSCR, Mount Sinai, New York, NY
Date/Time: Sunday 4th June 8.00am-11.00am
-End-
Contacts
Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Investor Relations
Graham Morrell
graham.morrell@bergenbio.com
Media Relations
Jan Lilleby
jl@lillebyfrisch.no
+47 90 55 16 98
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
